Dementia Flashcards

1
Q

What abnormal proteins are associated with Parkinson’s disase and Alzheimer’s dementia?

A

Parkinson’s disease - alpha synuclein

Alzheimer’s disease - APP and Abeta amyloid

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Most common neurodegenerative condition?

A

AD - >90% of overall; 1:300

PD - 1:5000

DLB - 6:100000

FTD - 3:100000

HD - 6:1000000

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Incidence of Alzheimer’s?

A

1% at age 60, doubles every 5 years thereafter (at 85 years 32%)

Higher in hispanics, african american

Lower in asians

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Natural history of Alzheimer’s disease?

A

Normal –> Preclinical (25 years) –> Prodromal “MCI” (5-8 years) –> Dementia (~9-10 years)

Episodic memory –> Semantic memory –> Attention, Executive (frontal, Visuospatial

Spread (particularly tau protein - neurofibriliary tangles):

Medial temporal –> temporal neocortex –> other multimodal association cortex

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Other symptoms associated with amnestic AD?

A

Weight loss (40%), insomnia, circadian rhythm changes

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Acute onset or very rapid progression of cognition - what would be likely diagnosis?

A

Prion disease, autoimmune, infectious, cancer, toxic-metabolic, and vascular causes, leukoencephalopathies.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

Atypical presentations of Alzheimer’s disease?

A
  1. Logopaenic primary progressive aphasia
    1. Hesitant, word-finding pauses, empty, paraphasia, impaired phase repetition
  2. Posterior cortical atrophy
    1. Biparietal: dorsal “where” pathway (location) –> apraxia, Gerstmann’s syndrome
    2. Occipto-temporal: ventral “what” pathway (object, face, word), agnosia, alexia
  3. Frontal variant AD
    1. Executive > behavioural deficits
  4. Visual variant (occipital lobe)
    1. Cortical blindness
  5. Acalculia variant (inferior parietal lobe)
    1. Relatively pure numerical and symbol difficulties
  6. Congophilic angiopathy
    1. Micro or lobar haemorrhages, superficial siderosis, amyloid angiitis (inflammatory changes)
    2. Associated with transient neurological deficits
    3. Occurs alone or in most patients with AD 90%
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Pathology of AD?

A

Microscopic:

Misfolded protein accumulation is the likely basis of AD

  1. Beta amyloid oligomers
    1. Disrupt synapses as earliest toxic change
    2. Although Abeta40 higher concentration, less toxic than Abeta42 which is also more prone to aggregate into oligomers
  2. Fibrillar beta amyloid
    • Form plaques, probably not toxic
  3. Tau pathology
    • May be secondary to beta-amyloid accumulation (abnormal phosphorylated may be triggered by trimeric ABeta*56

APP (amyloid precursor protein) Ch21 – [broken down inappropriately by beta and gamma secretase] –> beta amyloid –> aggregrates causing amyloid plaques – [+tau pathology and inflammation] –> Neuronal loss and AD

  • Reduced clearance of AB protein in patient with AD - many different mechanisms postulated however poorly understood
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is amyloid precursor protein and what is its involvement in the pathogenesis of AD?

A
  • Amyloid precursor protein found on Ch21
  • APP – [broken down inappropriately by beta and gamma secretase] –> beta amyloid –> aggregrates causing amyloid plaques – [+tau pathology and inflammation] –> Neuronal loss and AD
  • Reduced clearance of AB protein in patient with AD - many different mechanisms postulated however poorly understoo
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is tau?

A
  • Microtubules are held together by tau protein
  • Tau protein important for integrity of cytoskeleton and transport of molecules up and down neuron
  • In AD: hyperphosphorylated tau loses affinity for tubule binding domain and destabilizes tubules impairing axonal transport
  • Symptoms correlate with spread
    • Braak and Braak NFT stages
    • Hippocampal/enterhinal –> association cortex, prefrontal cortex –> temporal lobe
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Synaptic changes in AD?

A
  1. Hippocampal synapses preferentially vulnerable (activity dependent) - ? neurogenesis
  2. Impairs impulse transmission
    1. LTP loses to long term depression
  3. Abnormal endocytosis of NMDA and AMPA surface receptors
  4. Increased turnover and synapse loss is very early change (UDP, choline, DHA)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Genetics in AD?

A

Cause AD (almost 100% penetrance; Autosomal Dominant)

  • Presenilin 1 and 2
  • APP

Risk factors

  • ADAM10
  • ApoE4 (if 2 then higher risk)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Early onset familial AD

A
  • ~40% of all EOAD
  • Amyloid cascade hypothesis
    • Increased beta-A
    • Neurotoxic soluble oligomeric fibrils –> inert plaques
  • APP mutations
    • Ch21 (overproduction in Down’s syndrome)
    • Mutations disrupt normal APP processing
    • Clustered at APP secretase cleavage sites
  • Genetics: Presenilin 1 most common, then Presenilin 2
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is presenilin?

A
  • 4 proteins forming gamma-secretase (cleaves APP –> beta amyloid)
  • Modulates calcium homeostasis
  • Mutations result in increased beta-amyloid
  • PS1 mutations = major cause of EOFAD Ch 14; develop in 20s, severely disabled by early 40s
  • PS2 mutations = variable penetrance, 40-75+ years onset, 12 mutations, Ch 1
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Late onset AD genetic and environment risk factors?

A

Genetic risk factors

  • ApoE - e4 allelle Ch 19
    • Age-specific risk: 10 years earlier per e4 allele
    • Females increased risk (esp between 65-75)
  • Accelerators of beta amyloid deposition: ABCA7, FERMT2

Environment risk factors

  • AGE
  • Family hx
  • Female sex, singlehood/widowed
  • CV risk factors, congenital heart disease
  • Low education, leisure activities, socialisation, physical inactivity, cynicism, mid-life depression (higher in beta amyloid persons)

Protective factors

  • Physical exercise
  • ? education/stimulation
  • ? Oest/HRT
  • [statins, fish oil, NSAIDs] -> no benefit
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Criteria for preclinical AD?

A
  1. Asymptomatic cerebral amyloidosis
    * Amyloid biomarkers positive (A+)
  2. 1 + “downstream” neurodegeneration
    * Amyloid and neuronal injury markers (A+N+)
  3. 2 + subtle cognitive/behavioural decline
    * Additional subtle cognitive change (A+N+C+ or A+C+MCI)
17
Q

Primary age-related tauopathy (PART)

A
  • Identical neuronal NFTs to those of AD without ABeta pathology
  • Medial temporal lobe, basal forebrain, hypothalamus, thalamus, brainstem, olfactory nerve
  • Increases with age
  • Average age at death higher than AD
  • Asymptomatic to mild axial amnesia
  • Rarely leads to severe impairment
  • Lower ApoE4
  • MRI - medial temporal lobe atrophy
18
Q

Argyrophilic grain disease (AGD)

A
  • Tauopathy “grains” in hippocampus and amygdala
  • Pathology can be found at autopsy in late-onset amnestic syndromes and less commonly FTD spectrum disorders
  • Personality changes + paranoid hallucinations
19
Q

Limbic-predominant age related TDP43opathy encephalopathy (LATE)

A
  • Relatively common neuropathological finding
  • Cell loss and gliosis in hippcampus not explained in AD
  • NO association with ApoE4
  • Atherosclerotic changes common
  • Increases with age >85, whilst prevalence of AD decreases
  • Significant amnesia
  • Commonest cause of Abeta and tay-PET negative AD mimic
20
Q

Factors that prevent AD?

A
  1. Exercise and diet
    • Improvement in global cognition and episodic memory
    • Mediterranean diet - possibly effective
  2. Vascular risk factors
    • HTN

Things that don’t help:

  • Oestrogens, statins, NSAIDs, Gingko biloba, Vit E, Omega-3, homocysteine lowering therapy (i.e. giving folate) does not help
21
Q

Treatment of prodromal AD/MCI?

A
  1. Aerobic exercise
  2. Souvenaid
    • Medical food supplement - 2 year efficacy
    • Contains essential components for membrane regeneration
  3. Other
    • Socialisation, Mediterranean diet
    • No evidence of cognitive stimulation yet
22
Q
A
23
Q

Treatment of Alzheimer’s dementia?

A

Acetylcholinesterase inhibitors

  1. Donepezil (Aricept)
  2. Rivastigmine (Exelon) patch
  3. Galantamine (Reminyl)
  • Indication: Mild-Moderate AD. Need MMSE >10.
  • Contradications: asthma, peptic ulcer, conduction defects (do ECG)
  • Side effects: GIT, cramps, insomnia, cholinergic
  • Efficacy:
    • Mod-severe AD MMSE <17
    • DLB - rivastigmine > donepezil
    • Vasc dementia - donepezil, galantamine

Memantine (Ebixa)

  • Noncompetitive NMDA antagonist
  • Efficacy shown in mod-severe AD
  • Combination with AChEIs - added benefit when added to donepezil
  • Side effect: drowsiness